Kosuke Takemura

Jul 11, 2024 | bmjoncology.bmj.com | Kosuke Takemura

Systemic therapies for advanced renal cell carcinoma (aRCC) have evolved dramatically since the approvals of immuno-oncology (IO) agents.1 Thereafter, risk-based decision-making has become increasingly important to guide treatment selection.

Jan 29, 2024 | europeanurology.com | Kosuke Takemura |Matthew Ernst |J. Connor Wells |Audreylie Lemelin |Renee Maria Saliby |Talal El Zarif | +10 more

AbstractPatients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy.

Mar 23, 2023 | urotoday.com | Kosuke Takemura

Read the Full Video TranscriptPedro Barata: I'm very happy to be joined today by Dr. Takemura. Dr. Takemura is a urologist and doing a medical oncology fellowship with Dr. Daniel Heng in Calgary, Canada. And so welcome Dr. Takemura. Kosuke Takemura: Thank you very much. Pedro Barata: Thank you for taking the time to be with us today. Kosuke Takemura: My pleasure. Pedro Barata: Congratulations on your work. Great presentation at ASCO GU, important project. It comes out of the IMDC database, right?